Association of caffeine consumption with memory deficits and cerebrospinal fluid biomarkers in Mild Cognitive Impairment and Alzheimer’s Disease: a BALTAZAR cohort study

STRUCTURED ABSTRACT INTRODUCTION We investigated the link between habitual caffeine intake with memory deficits and CSF AD biomarkers in Mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) patients. METHODS MCI (N=147) and AD (N=116) patients of the BALTAZAR longitudinal cohort reported their caffeine intake using a dedicated survey and were followed-up for 3 years. Associations of caffeine consumption with cognition, MMSE decline and CSF biomarkers (Tau, pTau181, Aβ 1-42 , Aβ 1-40 ) were analyzed using logistic and ANCOVA models. RESULTS Adjusted on APOEε4, age, sex, education level and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 95%CI: 1.13 to 5.46; p=0.023) and lower CSF Aβ 1-42 (p=0.047), Aβ 1-42 / Aβ 1-40 (p=0.040) and Aβ 1-42 /pTau (p=0.020) in the whole cohort and a faster MMSE decline in amnestic MCI (p=0.024). DISCUSSION Data supports the beneficial effect of caffeine consumption to memory decline and CSF amyloid markers in MCI and AD patients.